Re-attendance among women eligible to enrol in a future microbicide trial.

1 At baseline, there were 1573 attendees. Of these 1156 (73.5%) were HIV negative, 1409 (89.6%) were not pregnant, and 1020 (64.8%) were both HIV negative and not-pregnant and therefore met broad eligibility criteria for enrolment into a future microbicide trial.2 At the 3-month clinic visit, 778/1020 (76.3%) women originally considered eligible for enrolment re-attended; 7/778 women sero-converted between baseline and 3 mo. visits leaving a total of 771 ‘eligible’ women at 3-months.3 Attendance = % of all possible follow-up visits that were actually attended.